Status
Not yet recruiting
Phase
Not applicable
Enrollment
200
Locations
1
Results
Not posted
Publications
0
Study summary
The goal of this clinical trial is to determine whether tirzepatide can reduce atrial fibrillation (AF) burden after catheter ablation in overweight or obese patients with persistent AF. It will also evaluate the effects of tirzepatide on body weight, metabolic risk factors, and clinical outcomes, as well as its safety and tolerability in this population. The main questions it aims to answer are: 1. Does peri-procedural treatment with tirzepatide reduce AF burden at 3 months after de novo catheter ablation, as measured by 7-day continuous ECG patch monitoring? 2. Does tirzepatide lead to greater weight loss and improvement in metabolic parameters compared with standard care alone? 3. Does tirzepatide reduce AF recurrence and cardiovascular events during 12 months of follow-up? Researchers will conduct a multi-center, open-label, endpoint-blinded, randomized controlled trial in adults aged 18-80 years with persistent AF and body mass index ≥25 kg/m² who are scheduled for de novo catheter ablation. Participants will be randomized 1:1 to receive either tirzepatide plus standard peri-procedural and post-ablation care or standard care alone. Participants in the tirzepatide group will receive subcutaneous tirzepatide 2.5 mg once weekly starting about 4 weeks before ablation and continuing for 3 months afterward, for a total treatment duration of approximately 4 months. All participants will be followed at 1, 2, 3, 6, and 12 months after ablation, with detailed assessment of AF burden, AF recurrence, echocardiographic parameters, metabolic profile, quality of life by the AFEQT questionnaire, and safety events.
Atrial fibrillation (AF) is one of the most common sustained arrhythmias and is associated with increased risks of stroke, heart failure, cognitive decline, and mortality, creating a substantial burden for patients and healthcare systems. Catheter ablation has become an important rhythm-control strategy that can restore sinus rhythm and improve quality of life in patients with AF. However, 30-50% of patients still experience recurrent atrial tachyarrhythmias after ablation, and higher AF burden has been linked to worse clinical outcomes, making AF burden a clinically relevant endpoint beyond a simple yes/no definition of recurrence. Obesity and metabolic dysfunction are major upstream drivers of AF, promoting atrial structural and electrical remodeling through hemodynamic load, epicardial fat accumulation, systemic inflammation, and neurohormonal activation. Intensive lifestyle and risk-factor management programs can reduce AF burden and improve ablation outcomes, but such interventions are often difficult to implement and sustain in routine practice. Pharmacologic therapies that induce substantial and durable weight loss and improve cardiometabolic risk may therefore offer a practical strategy to lower AF burden after ablation in overweight or obese patients. Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist that has produced large and sustained weight loss and broad cardiometabolic benefits in patients with obesity and type 2 diabetes, including improvements in glycemic control, blood pressure, and lipid profiles. In high-risk cardiometabolic populations, tirzepatide has also been associated with reductions in heart failure events and markers of congestion, suggesting favorable effects on cardiac loading conditions and structural remodeling. These data provide a strong rationale to test whether tirzepatide-induced weight loss and metabolic improvement can translate into reduced AF burden after catheter ablation. The TREAT-AF trial is an investigator-initiated, multi-center, open-label, endpoint-blinded randomized controlled trial in adults with persistent AF and body mass index ≥25 kg/m² who are scheduled for de novo catheter ablation. Participants are randomized 1:1 to receive peri-procedural tirzepatide in addition to standard care or standard care alone. Tirzepatide is started approximately 4 weeks before the ablation procedure and continued for 3 months afterward, aligning pharmacologic weight loss and metabolic optimization with the period of atrial healing and electrical remodeling after ablation. AF burden at 3 months is assessed by 7-day single-lead ECG patches and adjudicated by a blinded endpoint assessment committee. Secondary assessments include AF recurrence, echocardiographic measures of left atrial structure, metabolic parameters, quality of life using the AFEQT questionnaire, and cardiovascular events through 12 months of follow-up.
Interventions
DRUG
Subcutaneous tirzepatide 2.5 mg once weekly, initiated approximately 4 weeks before the scheduled de novo catheter ablation and continued for 3 months after the procedure (total treatment duration about 4 months), in addition to standard peri-procedural and post-ablation care.
OTHER
Standard peri-procedural and post-ablation care for persistent atrial fibrillation without tirzepatide or other study-specific metabolic pharmacotherapy.
Timeline
First posted
Feb 2, 2026
Study start
Jun 16, 2026
Primary completion
Dec 31, 2027
Study completion
Jul 31, 2028
Results posted
Not reported
Registry updated
Jun 12, 2026
Outcomes
Atrial fibrillation burden at 3 months after catheter ablation
Time frame · 3 months after catheter ablation (7-day ECG patch monitoring period)
AF burden is defined as the proportion of time an individual is in any atrial tachyarrhythmia (atrial fibrillation, atrial flutter, or atrial tachycardia) during a 7-day monitoring period, assessed using continuous single-lead ECG patch recordings. AF burden will be adjudicated by a blinded Endpoint Assessment Committee based on de-identified ECG data.
Atrial fibrillation recurrence within 3 months after catheter ablation
Time frame · From the date of ablation to 3 months after ablation
AF recurrence is defined as the first documented episode of any atrial tachyarrhythmia (atrial fibrillation, atrial flutter, or atrial tachycardia) lasting ≥30 seconds, detected by ECG monitoring or clinically indicated ECG during the first 3 months after ablation. Episodes occurring within a standard blanking period, if applicable, will be handled according to the study protocol.
Change in left atrial structure by echocardiography at 3 months
Time frame · Baseline and 3 months after ablation
Change from baseline to 3 months in echocardiographic measures of left atrial structure (left atrial volume indices), assessed by transthoracic echocardiography according to standard guidelines.
Change in atrial fibrillation-related quality of life questionnaire
Time frame · Baseline and 3 months after ablation
Change from baseline to 3 months in health-related quality of life as measured by the Atrial Fibrillation Effect on Quality of Life (AFEQT) questionnaire, using a validated Chinese version for Chinese-speaking participants. Higher scores indicate better quality of life.
Atrial fibrillation recurrence within 12 months after catheter ablation
Time frame · From the date of ablation to 12 months after ablation
Time to first recurrence of any atrial tachyarrhythmia (atrial fibrillation, atrial flutter, or atrial tachycardia) lasting ≥30 seconds, detected by ECG or rhythm monitoring during 12 months of follow-up after ablation.
Cardiovascular death or cardiovascular hospitalization within 12 months
Time frame · From the date of ablation to 12 months after ablation
Composite of cardiovascular death or hospitalization for cardiovascular causes (e.g., heart failure, acute coronary syndrome, stroke, or other predefined cardiovascular events), defined according to consensus cardiovascular endpoint definitions and adjudicated by the Endpoint Assessment Committee.
Eligibility
Inclusion Criteria: 1. Age between 18 and 80 years. 2. Diagnosed with persistent atrial fibrillation and scheduled for de novo catheter ablation. 3. Body mass index (BMI) ≥27 kg/m² at screening accompanied by at least one weight-related comorbidity (including cardiovascular disease, hypertension, dyslipidemia, or prediabetes). 4. Able and willing to provide written informed consent. Exclusion Criteria: 1. Long-standing AF or marked left atrial enlargement (persistent AF duration \> 5 years or left atrial anterior-posterior diameter \> 50 mm). 2. AF secondary to reversible causes (e.g., hyperthyroidism, acute infection, acute pulmonary embolism, recent cardiac surgery). 3. Severe structural heart disease that may significantly affect ablation outcomes (e.g., hypertrophic cardiomyopathy, rheumatic valvular disease, dilated cardiomyopathy). 4. Planned major non-AF-related surgery or interventional procedure within 3 months. 5. Other arrhythmias requiring chronic antiarrhythmic drug therapy. 6. Intracardiac thrombus or any contraindication to catheter ablation as judged by the investigator. 7. Active systemic infection at screening. 8. Contraindications to tirzepatide or GLP-1/GIP receptor agonists (e.g., prior serious hypersensitivity, personal or family history of medullary thyroid carcinoma or MEN2, history of clinically significant pancreatitis, severe gastrointestinal disease that may impair tolerance or absorption). 9. Poorly controlled type 1 diabetes, recent diabetic ketoacidosis, end-stage renal disease requiring dialysis, or severe hepatic dysfunction judged clinically significant. 10. Pregnancy, breastfeeding, or women of childbearing potential unwilling or unable to use adequate contraception during the study. 11. Participation in another interventional clinical study within 30 days prior to screening or planned participation during the study period. 12. Any other condition that, in the opinion of the investigator, makes the patient unsuitable for participation, including inability to comply with study procedures or follow-up.
Study locations
Taiwan. Showing up to 24 locations stored in the fast local snapshot.
National Taiwan University Hospital Cardiovascular Center
Taipei, Taiwan
Publications
No PMID-linked publications were present in this registry snapshot.
Related trials
The Cleveland Clinic · Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) · Non-Alcoholic Fatty Liver Disease
Phase 4
Recruiting
120
2026-07
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · Obesity & Overweight
Not applicable
Recruiting
24
2026-07
Shahid Beheshti University of Medical Sciences · Heart Failure and Reduced Ejection Fraction · Obesity & Overweight
Phase 3
Not yet recruiting
60
2026-07
Texas Tech University · Obesity & Overweight · Cardiometabolic Health Indicators
Not applicable
Recruiting
27
2026-07
Alaa Sada · Mild Autonomous Cortisol Secretion (MACS) · Adrenalectomy; Status
Phase 2
Recruiting
34
2026-07
yifang zhu · Acute Ischemic Stroke (AIS)
Phase 2 / Phase 3
Not yet recruiting
430
2026-07
Johns Hopkins University · Central Centrifugal Cicatricial Alopecia (CCCA)
Phase 2
Not yet recruiting
20
2026-07
Duke University · Idiopathic Intracranial Hypertension (IIH)
Phase 4
Not yet recruiting
60
2026-07
Related PeptideStat pages
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.